Cash flow remains highly unstable, with free cash flow swinging from a $11.5 million peak in 2025Q2 to a $3.4 million deficit in 2025Q4, complicated by a persistent $776.6K quarterly dividend payment despite ongoing net losses.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Cash from Operations | 5.66M | 8.28M | 17.51M | 8.82M | -22.94M | -33.09M | -12.13M | 251.41K | -905.52K | -817.22K | -407.91K | -295.12K | 33.44K | -259.07K | -229.73K | -17.69K |
| Operating CF Margin % | - | 4.27% | 8.24% | 5.78% | -19.27% | -35.62% | -32.53% | 2.02% | -10.88% | -16.17% | -7.79% | -24.21% | 4.68% | -32.05% | -34.1% | -2.38% |
| Operating CF Growth % | -406.75% | -52.72% | 98.56% | 138.46% | 30.68% | -172.72% | -4925.47% | 127.76% | -10.81% | -100.34% | -38.22% | -982.57% | 112.91% | -12.78% | -1198.91% | - |
| Net Income | -17.03M | 15.62M | -18.73M | -20.6M | -45.02M | -61.32M | -60.52M | -3.53M | -1.36M | -1.21M | -1.22M | -159.23K | -460.49K | -268.26K | -445.65K | -502.93K |
| Depreciation & Amortization | -2.76M | 328.37K | 9.49M | 6.6M | 3.77M | 868.76K | 397.76K | 335.61K | 195.78K | 91.56K | 33.72K | 43.75K | 56.98K | 56.97K | 56.97K | 56.69K |
| Stock-Based Compensation | 7.95M | 10.5M | 12.23M | 12.49M | 13.73M | 12.07M | 18.66M | 733.22K | 273.57K | 162.74K | 587.99K | 142.3K | 125.5K | 105K | 84K | 400K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 354K | 0 | 914.86K | 66K | 4K | -90.28K | 37.42K | -13.2K | -17.2K | -17.2K | -17.2K | -17.2K |
| Other Non-Cash Items | -4.94M | -10.31M | 1.87M | 5.42M | 5.78M | 6.17M | 19.63M | 578.61K | 237.2K | 918.01K | 33.72K | -127.26K | 80.5K | 48.75K | 122.31K | -17.2K |
| Working Capital Changes | 4.9M | -7.85M | 12.65M | 4.91M | -1.55M | 9.13M | 8.8M | 2.07M | -255.97K | -693.28K | 122.54K | -181.48K | 328.65K | -184.34K | -30.16K | 45.75K |
| Change in Receivables | 2.58M | 1.15M | -2.94M | -2.44M | -2.19M | 17.7K | -550.97K | 1.6K | 29.14K | 95.09K | -361.44K | -139.47K | 62.51K | -27.79K | -13.33K | 43.97K |
| Change in Inventory | 399.77K | 303.24K | 675.67K | 764.33K | -2.18M | -409.82K | -314.2K | 72.56K | -341.36K | -546.89K | -99.22K | -20.04K | 45.19K | -22.82K | -4.58K | 46.2K |
| Change in Payables | 11.08M | 3.24M | 4.92M | 978.06K | 1.25M | -893.96K | 8.93M | 1.89M | 6.34K | -227.23K | 585.45K | -21.97K | 88.96K | -1.73K | -12.24K | -134.41K |
| Cash from Investing | 7.72M | 6.91M | -11.54M | -8.73M | -13.91M | -3.4M | -798.14K | -100K | 141.44K | 63.38K | 219.89K | 127.26K | 0 | 0 | 0 | 0 |
| Capital Expenditures | -1.02M | 0 | -1.49M | -203.81K | -366.63K | -247.37K | -398.14K | 0 | -100K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | 0.46% | 0.96% | 0.7% | 0.13% | 0.31% | 0.27% | 1.07% | - | 1.2% | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | -1.01M | 0 | -400K | -100K | 241.44K | 63.38K | 219.89K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 8.74M | 6.91M | -10.05M | -8.53M | -12.53M | -3.15M | 0 | -100K | 290K | 0 | 0 | 127.26K | 0 | 0 | 0 | 0 |
| Cash from Financing | -13.29M | -13.41M | -4.12M | 29.1M | -528.2K | 68.64M | 21M | 775.12K | 802.79K | 776.03K | 357.49K | 325.35K | -113K | 315.2K | 295.15K | 51.19K |
| Debt Issued (Net) | -18.72M | -18.72M | -327.6K | 16.67M | 2.74M | -530.82K | 93.19K | 798.28K | 642.44K | 116.06K | 131.4K | 158K | -13K | 40.2K | -50.73K | -142.31K |
| Equity Issued (Net) | 9.27M | 9.19M | 0 | 16.2M | 0 | 69.33M | 20.13M | 350K | 0 | 596.6K | -23.8K | -10.8K | 0 | 175K | 345.88K | 193.5K |
| Dividends Paid | -3.11M | -3.11M | -3.11M | -3.11M | -3.11M | -871.48K | -1.29M | 0 | 0 | 0 | 0 | -10.8K | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -76.65K | -87.05K | -10.8K | 0 | 0 | 0 | 0 |
| Other Financing | -737.66K | -773.66K | -684.83K | -667.63K | -159.2K | 707.36K | 2.07M | -373.15K | 160.35K | 63.38K | 249.89K | 188.95K | -100K | 100K | 0 | 0 |
| Net Change in Cash | 84.73K | 1.78M | 1.86M | 29.19M | -37.37M | 32.15M | 8.07M | 926.53K | 38.71K | -41.18K | -50.42K | 157.49K | -79.56K | 56.13K | 65.43K | 33.5K |
| Free Cash Flow | 14.83M | 6.41M | 5.98M | 86.95K | -35.83M | -36.49M | -12.53M | 251.41K | -1.01M | -817.22K | -407.91K | -295.12K | 33.44K | -259.07K | -229.73K | -17.69K |
| FCF Margin % | 6.76% | 3.3% | 2.81% | 0.06% | -30.1% | -39.29% | -33.6% | 2.02% | -12.08% | -16.17% | -7.79% | -24.21% | 4.68% | -32.05% | -34.1% | -2.38% |
| FCF Growth % | 368.41% | 7.24% | 6774.08% | 100.24% | 1.81% | -191.21% | -5083.83% | 125% | -23.04% | -100.34% | -38.22% | -982.57% | 112.91% | -12.78% | -1198.91% | - |
| FCF per Share | 0.31 | 0.14 | 0.15 | 0.00 | -1.16 | -1.35 | -0.88 | 0.03 | -0.11 | -0.09 | -0.06 | -0.05 | 0.01 | -0.04 | -0.04 | -0.00 |
| FCF Conversion (FCF/Net Income) | -0.87x | -1.17x | -0.93x | -0.43x | 0.50x | 0.54x | 0.21x | -0.08x | 0.73x | 0.68x | 0.37x | 4.76x | -0.07x | 0.97x | 0.52x | 0.04x |
| Interest Paid | 0 | 0 | 0 | 0 | 189K | 435.05K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
High Customer Acquisition Costs
As reported in quarterly financial statements, LifeMD's operating cash flow frequently diverges from net income, with the OCF/NI ratio reaching an extreme -4.16 in 2025Q2, suggesting that reported earnings are not currently serving as a reliable proxy for the company's actual cash-generating capabilities.
The persistent gap between net income and operating cash flow indicates that non-cash items and working capital fluctuations are heavily influencing the bottom line. Investors should monitor whether this disconnect reflects aggressive accrual accounting or simply the inherent volatility of a business model reliant on high-volume, low-margin customer acquisition.
Based on the company's reported figures, free cash flow has exhibited significant instability, swinging from a peak of $11.5 million in 2025Q2 to a deficit of $3.4 million in 2025Q4, highlighting the difficulty in maintaining consistent cash generation amidst a contracting revenue environment.
The erratic nature of FCF margins suggests that the company's cash flow is highly sensitive to timing differences in marketing spend and subscriber renewals. This lack of predictability makes it difficult to determine if the business is truly approaching a sustainable self-funding inflection point.
According to recent SEC filings, working capital changes have been a primary driver of cash flow volatility, with a notable $5.7 million inflow in 2026Q1 contrasting with a $5.2 million outflow in 2025Q4, indicating that operational cash flow is heavily dependent on timing shifts.
These large swings in working capital suggest that the company may be managing its payables and receivables aggressively to smooth out cash flow reporting. Such reliance on working capital management to bolster liquidity warrants further investigation into the underlying health of the core subscription business.
As disclosed in financial statements, LifeMD has maintained a consistent quarterly dividend payment of approximately $776.6K despite reporting net losses in most periods, which appears to be a strategic choice to return capital to shareholders while the core business remains in a cash-burning phase.
The decision to continue dividend payments while operating cash flow remains inconsistent suggests a management focus on shareholder optics. However, this capital allocation strategy may limit the resources available for reinvestment into the clinical infrastructure necessary to drive long-term, non-marketing-dependent growth.
Quick answers to the most common questions about buying LFMD stock.
LifeMD, Inc. (LFMD) generated $8.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
LifeMD, Inc. (LFMD) generated $6.4M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
LifeMD, Inc. (LFMD) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, LifeMD, Inc. (LFMD) returned $3.1M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.